# Safety, Tolerability and Efficacy of Adjunctive TBO-309 in Reperfusion for Stroke With Tandem Occlusion

> **NCT06813651** · PHASE2 · RECRUITING · sponsor: **ThromBio Pty. Ltd.** · enrollment: 78 (estimated)

## Conditions studied

- Ischemic Stroke
- Tandem Occlusion

## Interventions

- **DRUG:** TBO-309: 60 mg
- **DRUG:** TBO-309: 120 mg
- **DRUG:** TBO-309: 30 mg

## Key facts

- **NCT ID:** NCT06813651
- **Lead sponsor:** ThromBio Pty. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-04
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06813651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06813651, "Safety, Tolerability and Efficacy of Adjunctive TBO-309 in Reperfusion for Stroke With Tandem Occlusion". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06813651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*